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Abstract
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Prokaryotic aminoacylated-transfer RNAs often need to be efficiently segregated between
translation and other cellular biosynthetic pathways. Many clinically relevant bacteria, including
Streptococcus pneumoniae, Staphylococcus aureus, Enterococcus faecalis and Pseudomonas
aeruginosa direct some aminoacylated-tRNA species into peptidoglycan biosynthesis and/or
membrane phospholipid modification. Subsequent indirect peptidoglycan cross-linkage or change
in membrane permeability is often a prerequisite for high-level antibiotic resistance. In
Streptomycetes, aminoacylated-tRNA species are used for antibiotic synthesis as well as antibiotic
resistance. The direction of coding aminoacylated-tRNA molecules away from translation and into
antibiotic resistance and synthesis pathways are discussed in this review.
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1. Introduction
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Protein synthesis by ribosomes utilizes aminoacyl-tRNAs to translate the codons of mRNA
into the corresponding polypeptide sequence. Within the cell, each aminoacyl-tRNA species
is produced by a two-stage reaction that is catalyzed specifically by one of twenty
aminoacyl-tRNA synthetase enzymes (aaRSs). In the first stage of the reaction, an amino
acid is activated with adenosine triphosphate (ATP) to form an aminoacyl-adenylate with
concurrent release of inorganic pyrophosphate (PPi). In the second stage of the reaction, the
activated amino acid moiety is transferred either to the 2’ or the 3’ hydroxyl of adenine-76 at
the 3’ end of the bound tRNA substrate with the subsequent formation of an aminoacyl-ester
bond [1,2]. Following this process, the aminoacylated-tRNA product is released and
sequestered by elongation factor Tu (EF-Tu) for delivery to the ribosome and use in protein
synthesis (Fig. 1) [3,4]. Aminoacylated tRNA substrates are also required for cellular
processes outside of translation including both peptidoglycan and antibiotic biosynthesis
pathways in prokaryotes (Fig. 2). The processes that sequester aminoacyl-tRNAs away from
translation so that they can, instead, be used in other specific biosynthetic pathways will be
discussed in this review.
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2. Direction of aminoacyl-tRNA into peptidoglycan biosynthesis
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Peptidoglycan is a key component of the bacterial cell wall responsible for providing
protection against osmotic stress and turgor pressure [5]. It forms a thicker layer in Grampositive bacteria, many of which also heavily use the structure for anchoring of important
virulence factors, when compared to Gram-negative bacteria [6]. The carbohydrate
backbone of peptidoglycan consists of an alternating chain of N-acetylglucosamine
(GlucNAc) and N-acetylmuramic acid (MurNAc) residues with a pentapeptide side chain
attached to the lactyl ether appendage of the latter component. A single GlucNAc-MurNAc
pentapeptide subunit in combination with undecaprenyl-pyrophosphate is the building block
for peptidoglycan formation and is commonly referred to as Lipid II. Pentapeptide side
chains are comprised of alternating D- and L- amino acids with an overall common structure
of L-Ala-γ-D-Glu-X-D-Ala-D-Ala. Gram-negative bacteria typically have mesodiaminopimelic acid at position X whereas in Gram-positive bacteria this is replaced most
frequently by L-Lys [7]. An additional level of peptidoglycan structure is obtained by crosslinking between the pentapeptide side chains of adjacent strands. The rigidity of the final
murein structure is dictated by the degree of cross-linking. Typically Gram-negative
bacteria, such as Escherichia coli, have a low level of pentapeptide cross-linking (25–50%)
in comparison to Gram-positive bacteria (70–90%). In addition to this, cross-links can either
be direct, involving linkage of the amino acid at position X of the first pentapeptide side
chain with the L-Ala at the fourth position of another, or indirect which first requires the
formation of a connecting amino acid bridge. Indirect cross-linking is more common in
bacteria that have L-Lys at position X and the structure of the required intervening amino
acid bridge can vary between different genera and species [7,8]. The amino acids required
for bridge formation are typically derived from appropriately aminoacylated-tRNA donor
molecules. Utilization of these donor tRNA molecules in peptidoglycan biosynthesis and
how this relates to antibiotic resistance, are discussed below.
2.1. MurM and MurN in Streptococcus pneumoniae

NIH-PA Author Manuscript

The peptidoglycan layer of S. pneumoniae is unusual in that it contains a combination of
both linear and branched muropeptides within the structure. Branched muropeptides carry
either an L-Ala-L-Ala or an L-Ser-L-Ala dipeptide that is attached to the third L-Lys of the
pentapeptide side chain of Lipid II [9] (Fig. 3). Formation of this dipeptide substrate for
indirect peptidoglycan cross-linking requires the activities of the MurM and MurN tRNAdependent aminoacyl-ligases. MurM and MurN are encoded within an operon by the fibA
and fibB (factors important in β-lactam resistance) genes, respectively. In addition, MurMN
activity is functionally conserved across all strains of pneumococcus [10,11]. Selective
inactivation of these two genes has shown that the protein products act within a specific
order. MurM is responsible for the addition of either L-Ala or L-Ser as the first amino acid
of the cross-link and then MurN invariably adds L-Ala as the second amino acid [12]. In
both cases, appropriately aminoacylated-tRNA species serve as the amino acid donors for
the reaction [13]. Provision of adequate substrates for MurMN is currently thought to be
achieved solely by the activities of alanyl- and seryl-tRNA synthetases within this
bacterium. No MurMN-specific tRNA isoacceptors have been identified to date that would
explain how a balance between direction of these aminoacylated-tRNA species into the
protein and peptidoglycan biosynthesis pathways is either established or maintained.
In 1990, prior to the identification of the fibAB operon, a link was established between
levels of indirect cross-linking in the pneumococcal cell wall and penicillin resistance. At
this time, it was observed that a penicillin-resistant isolate from South Africa had a highly
branched peptidoglycan that could be co-transferred with penicillin resistance to susceptible
pneumococci [14,15]. Since then, many highly penicillin-resistant strains of pneumococcus
have also been shown to have an increased level of branched muropeptides within their cell
FEBS Lett. Author manuscript; available in PMC 2014 September 17.
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wall in comparison to penicillin-sensitive isolates. Further investigation by insertion
duplication mutagenesis targeting the fibAB operon showed that inactivation of MurMN had
no significant effect on cell viability. Notably, interruption of the fibAB operon in S.
pneumoniae strain Pen6 caused a marked reduction in penicillin resistance from 6 µg mL−1
to 0.032 µg mL−1. This effect was also seen in other penicillin-resistant strains of
pneumococcus regardless of their genetic background, labeling MurM and MurN as the first
major non-penicillin binding protein determinants of β-lactam resistance within this
bacterium [10].
Further elucidation of the role of MurMN in β-lactam resistance has been complicated by the
finding that transformation with a MurM allele from a penicillin-resistant strain enriches
branched muropeptides but does not increase penicillin-resistance. This suggests that, whilst
MurM is necessary for high-level penicillin resistance, it is not sufficient in the absence of
low affinity forms of the penicillin binding proteins. It has also been demonstrated that
inactivation of murMN results in increased susceptibility to cell lysis during exposure to low
concentrations of other antibiotics that target peptidoglycan biosynthesis including
fosfomycin, vancomycin, D-cycloserine and nisin. This is predictive of stress response
mediated re-direction of aminoacylated-tRNA species into peptidoglycan biosynthesis via
the MurM and MurN proteins [12,16,17].

NIH-PA Author Manuscript

2.2. FemXAB in Staphylococcus aureus
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Indirect cross-linking within the peptidoglycan of S. aureus requires modification of the
Lipid II intermediate with a pentaglycine bridge, which is subsequently used as a platform
for anchoring many virulence factors within this bacterium [5,18]. Pentaglycine bridge
formation is catalyzed in a three-step process by the tRNA-dependent aminoacyl ligases
FemX (FhmB), FemA and FemB. The genes encoding FemXAB are transcribed from an
operon and the protein products act in a specific order. FemX is responsible for addition of
the first Gly residue of the bridge [19,20]. Following this, FemA sequentially adds two more
Gly residues prior to pentaglycine bridge completion by FemB. All three of these proteins
require Gly-tRNAGly as the amino acid donor and adequate provision of this substrate
within the cell is achieved by glycyl-tRNA synthetase [21]. This is, in part, aided by the fact
that three out of the five tRNAGly isoacceptors encoded in the S. aureus genome have
sequence identity elements consistent with weak binding to EF-Tu [22]. These specific
sequence elements include replacement of the strong EF-Tu binding pairs G49–U65 and
G51–C63 [23–25] with A49–U65 and A51–U63, respectively, in the TΨC loop. In addition
the three non-proteinogenic tRNAGly isoacceptors also exhibit replacement of GG at
positions 18 and 19 with either UU or CU [22]. This allows S. aureus to maintain adequate
provision of Gly-tRNAGly for two essential processes: translation and cell wall modification
by the FemXAB proteins, even though it only has one glycyl-tRNA synthetase encoded in
its genome [22].
Determination of the X-ray crystal structure of FemA indicated that the protein likely has
only one binding site for Gly-tRNAGly [26]. This initially indicated that an additional
aminoacyl-tRNA binding event would be required for transfer of the second Gly residue by
this protein. Further studies resulted in the detection of protein-protein interactions between
two monomers of FemA, two monomers of FemB and also between FemA and FemB
directly. No such interactions were found for FemX [27]. This suggests that FemX carries
out its function as a monomer whereas FemA and FemB carry out their functions as
homodimers. Dimerization of two FemA monomers and then, in a separate event, two FemB
monomers, would allow for transfer of one Gly residue to Lipid II by each of the proteins in
the dimer without the need for an additional tRNA binding event [27].
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In contrast to S. pneumoniae, indirect peptidoglycan cross-linking in S. aureus is essential
for cell viability as determined by femX inactivation studies. Furthermore, selective femA or
femB inactivation was determined to be lethal without the acquisition of complementary
mutations due to a combination of phenotypic effects. These effects included reduction in
the cell wall Gly content, reduction in cell wall turnover, disruption to cell septum
formation, retarded separation of cells and loss of methicillin resistance with concurrent
increase in sensitivity to β-lactam antibiotics [28–30]. These detrimental effects make
sequestration of Gly-tRNAGly away from protein synthesis and into peptidoglycan synthesis
essential in this bacterium.
2.3. Lif and Epr in Staphylococcus simulans and Staphylococcus capitis
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Both S. simulans and S. capitis produce glycyl-glycine endopeptidases that specifically
target and cleave the pentaglycine bridge that is formed during indirect cross-linking of
staphylococcal peptidoglycan. Possession of such endopeptidases confers a competitive
advantage on these particular bacteria during niche colonization in the presence of other
staphylococcal species. In order to protect itself from its own endopeptidase (lysostaphin), S.
simulans specifically produces lysostaphin immunity factor, otherwise known as Lif [31].
Similarly, S. capitis produces endopeptidase resistance factor, or Epr, to provide protection
against its endopeptidase Ale-1 [32]. Lif and Epr have been shown to have up to 41%
identity to FemAB and, therefore, it is no surprise that they require aminoacylated-tRNA
species for their function. Lif and Epr have a high specificity for incorporation of Ser instead
of Gly at the third and fifth position of the typical staphylococcal pentaglycine bridge. The
resulting peptidoglycan structure, which has an interpeptide bridge comprised of alternating
Ser and Gly, is protected from hydrolysis by the glycyl-glycine endopeptidases as they are
unable to break the peptide bonds between these two amino acids [33]. Currently, it is not
known how Lif and Epr hijack SertRNASer away from protein synthesis, however, neither of
these proteins are able to extend the monoglycine bridge found in femAB deletion strains.
Therefore it is clear that they depend on FemA and FemB in some way for activity [33]. LSer has also been detected in the peptidoglycan cross-links of other staphylococci including
S. epidermidis [34].
2.4. FemX in Weissella viridescens
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In W. viridescens, indirect peptidoglycan cross-linking involves the formation of an L-AlaL-Ser or an L-Ala-L-Ser-L-Ala peptide bridge. Within this bacterium, the Ala-tRNAdependent enzyme, FemX, achieves initiation of peptide bridge formation by transfer of the
first L-Ala residue to the epsilon amino group of L-Lys found at the third position of the
pentapeptide side chain. The enzymes involved in the subsequent transfer of the second
position Ser and third position Ala residues have not yet been formally identified [35]. In
contrast to the substrate specificity of many of the other Fem enzymes, W. viridescens
FemX exclusively utilizes the cytoplasmic peptidoglycan precursor, UDP-MurNAc
pentapeptide, rather than membrane bound Lipid II [36]. Kinetic characterization of W.
viridescens FemX has indicated that its catalytic mechanism can be divided into four highly
ordered and sequential stages. In the first two stages, the enzyme binds to UDP-MurNAc
and then to Ala-tRNAAla. In the third stage, L-Ala is transferred from the bound tRNA
donor molecule to the accepting L-lys at the third position of the pentapeptide side chain.
Finally the reaction is completed by release of the tRNA donor and the UDP-MurNAc
hexapeptide product. Asp-108 has been identified as an essential residue within FemX since
mutation to Asn is directly correlated with a 230-fold reduction in the catalytic efficiency of
the enzyme [37]. Recent crystallization of FemX in complex with a peptidyl-tRNA
conjugate has identified Lys-305 and Phe-304 as additional critical residues for optimal
catalytic activity of the enzyme. Replacement of Lys-305 with Ala, Met or Arg decreases
the turnover number of the enzyme by 1.3 × 104-, 1.9 × 102- and 9.9 × 102- fold,
FEBS Lett. Author manuscript; available in PMC 2014 September 17.
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respectively. The critical nature of this highly conserved Fem-ligase family residue is likely
due to the amine stabilizing effect it has during the development of a negative charge on the
carbonyl group of L-Ala upon nucleophilic attack of the Ala-tRNAAla ester bond by the
amine group of L-Lysine in the pentapeptide side chain. In contrast, replacement of Phe-304
with Ala or Leu decreases the turnover number of the enzyme by 16- and 29-fold,
respectively. This is due to the critical nature of this residue in establishing correct stacking
interactions between the enzyme and its tRNA substrate [38].

NIH-PA Author Manuscript

The X-ray crystal structure of FemX shows that it has two domains, each with a distinct
role. The first domain of the protein is involved in the binding of UDP-MurNAc, whereas
the presence of a positively charged channel across domain II indicates a potential role in the
accommodation and binding of the negatively charged backbone of the Ala-tRNAAla
substrate [39]. Following on from this discovery, the interaction of FemX with its second
substrate has been characterized by the introduction of specific modifications within both
the tRNA and the amino acid moiety. These studies indicated that FemX has a preference
for L-Ala addition to UDP-MurNAc pentapeptide because it reacts much more unfavorably
with both L-Ser and the acceptor arm of tRNAGly. More specifically, in vitro activity assays
show that FemX turns over Ser-tRNASer and Gly-tRNAGly 17- and 38-fold less efficiently
than Ala-tRNAAla, respectively. In the latter case, this can be explained by site-directed
mutagenesis studies indicating the importance of the penultimate base pair of tRNAAla, G2–
C71, as an essential identity element for FemX. This is typically replaced by C2–G71 in
tRNAGly species [40]. Specific FemX residues involved in tRNA binding have been
identified by crystallization of the enzyme with a peptidyl-RNA conjugate and include
Ile-208, which forms a hydrophobic interaction with the CCA end of the aminoacyl-tRNA
substrate. In addition to this, Arg-205, Ser-259 and His-206 form a hydrogen-bonding
network that stabilizes the phosphates of the C75 and A76 nucleotides located at the 3’
terminus of the tRNA substrate [38]. W. viridescens FemX has been shown to specifically
transfer Ala from tRNA that is aminoacylated on the 2’ hydroxyl of adenine-76 of the tRNA
molecule [35,41]. This may account for successful substrate competition with the A site of
the ribosome which transfers amino acids from the 3’ hydroxyl of the tRNA using the 2’
hydroxyl as a catalyst for peptide bond formation [42].
2.5. BppA1 and BppA2 in Enterococcus faecalis
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The peptidoglycan of E. faecalis comprises a series of indirect cross-links that result from
the production of an L-Ala-L-Ala dipeptide bridge. The dipeptide bridge is attached to the
epsilon amino group of the third position L-Lys of the pentapeptide side chain in a process
that requires alanyl-tRNA synthetase, Ala-tRNAAla and the two Fem ligases BppA1 and
BppA2. BppA1 is responsible for transfer of the first Ala of the dipeptide to its cytoplasmic
precursor, UDP-MurNAc pentapeptide. BppA2 is subsequently responsible for transfer of
the second Ala residue. BppA1 and BppA2 are orthologues of the S. pneumoniae Fem
proteins sharing 39% identity to MurM and 38% identity to MurN at the amino acid level,
respectively. Deletion of BppA2 results in a peptidoglycan structure comprised of a monoAla bridge and simultaneous reduction in the intrinsic β-lactam resistance level of this
bacterium. Resistance of E. faecalis to third generation cephalosporins results from
production of a specific low affinity penicillin binding protein, PBP5, by nearly all members
of the species. Optimal activity of PBP5 requires peptidoglycan precursor substrates to carry
the completed di-Ala bridge [43]. Therefore, successful diversion of Ala-tRNAAla away
from protein synthesis and into this alternative pathway has direct effects on β-lactam
resistance. The mechanism by which Ala-tRNAAla partitioning is achieved in E. faecalis to
ensure adequate provision of this substrate for both protein and peptidoglycan biosynthesis
is currently unknown.
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S. coelicolor peptidoglycan is indirectly cross-linked by virtue of a mono-Gly branch that is
attached to meso-diaminopimelic acid at the third position of the cytoplasmic UDP-MurNAc
pentapeptide side chain precursor. Mono-Gly branch formation is achieved by one of the
Gly-tRNA-dependent aminoacyl ligases FemX or VanK. FemX and VanK are not active at
the same time and control of their gene expression depends upon vancomycin levels in the
immediate environment of the bacterium. In the absence of vancomycin, FemX, which
recognizes UDP-MurNAc pentapeptide terminating in D-Ala-D-Ala, is active and
responsible for the addition of mono-Gly to the third position of the side chain. Conversely,
in the presence of this antibiotic, expression of the vancomycin gene cluster,
VanSRJKHAX, is switched on by the two component regulatory system VanRS [44].
Expression from this gene cluster results in VanHAX mediated termination of the
pentapeptide side chain of UDP-MurNAc in D-Ala-D-Lactate (Lac) instead of D-Ala-D-Ala.
Since vancomycin is unable to bind pentapeptide that terminates in D-Ala-D-Lac, this minor
change in the peptidoglycan precursor is enough to confer vancomycin resistance on S.
coelicolor. FemX is unable to recognize UDP-MurNAc pentapeptide terminating in D-AlaD-Lac and so cannot branch the precursor in the presence of vancomycin. Therefore, to
maintain cell viability in the presence of this antibiotic, FemX activity is substituted for by
VanK activity [45]. The factors involved in diversion of Gly-tRNAGly away from protein
synthesis and into peptidoglycan biosynthesis in S. coelicolor are currently unknown.
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3. Direction of aminoacylated-tRNA into antibiotic biosynthesis and
resistance pathways
In addition to having essential roles in protein synthesis and Gram-positive peptidoglycan
cross-linking, aminoacyl-tRNAs are also used in pathways directly implicated in antibiotic
biosynthesis and resistance. These reactions involve different amino acid-tRNA pairs and a
variety of acceptor molecules as discussed below.
3.1. MprF mediated antibiotic resistance
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MprF proteins are broadly defined as virulence factors that control the permeability of the
cell wall to cationic antimicrobials by catalyzing the aminoacylation of inner membrane
lipids (reviewed in [46]. Aminoacylation of membrane lipids adjusts the net negative charge
of the membrane bilayer in a manner that is dependent on the aminoacyl-tRNA substrate
[47]. The most well characterised MprF proteins are the aminoacyl-phosphatidylglycerol
synthases (aa-PGSs). The aa-PGSs are integral membrane proteins found in the cytoplasmic
membrane of both Gram-positive and Gram-negative bacteria. These enzymes are directly
responsible for the transfer of amino acids from aminoacyl-tRNA donors to the polar head
group of the common membrane lipid, phosphatidylglycerol [48]. In each case, aa-PGSs
have an N-terminal membrane-spanning domain that varies in length and is thought to be
involved in flipping the aminoacylated-phospholipid across the membrane. At the Cterminus, there is a separate hydrophilic domain that catalyzes the aminoacylation process
[49]. Some forms of aa- PGSs, including LysX in Mycobacterium tuberculosis, also have a
bound tRNA synthetase enzyme that is dedicated to providing the MprF part of the protein
with its charged tRNA substrate [50].
In some bacteria, including Clostridium perfringens, Staphylococcus aureus and
Mycobacterium tuberculosis, Lys-tRNALys is used both for translation and as a substrate for
the aminoacylation of membrane lipids [48,50–52]. Within these organisms, aa-PGSs
transfer the amino acid from LystRNALys to phosphatidylglycerol. The overall effect of this
process is an increase in the net positive charge of the cytoplasmic membrane. This
subsequently lowers permeability to cationic molecules including defensins,
FEBS Lett. Author manuscript; available in PMC 2014 September 17.
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aminoglycosides, β-lactams and glycopeptides. Recently, aa-PGSs that are able to transfer
amino acids other than Lys to phosphatidylglycerol have been discovered. C. perfringens
and Pseudomonas aeruginosa both have Ala-PGSs which are able to aminoacylate
phosphatidylglycerol with Ala and thus neutralize the overall charge of the membrane
[48,53]. This modification has been shown to enhance the resistance of P. aeruginosa to a
multitude of negatively charged β-lactam antibiotics such as oxacillin and methicillin as well
as providing protection against acidic or osmotically stressful growth conditions.
Enterococcus faecium has been shown to have an aa-PG with triple specificity for Ala, Arg
and Lys [54]. This is indicative of the fact that these aa-PG enzymes confer antibiotic
resistance by a combination of two mechanisms: lowering the net negative charge of the
membrane and altering its general biophysical properties including fluidity and permeability.
The latter of these two underexplored mechanisms could result in significant changes in the
membrane proteome and a shift in the expression of virulence phenotypes.
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The process of directing appropriately aminoacylated-tRNA donor molecules into
membrane lipid modification and away from protein synthesis is not fully understood. Since
MprF and EF-Tu have been demonstrated to have comparable affinities for Lys-tRNALys
under physiological conditions (Fig. 4, [53]), it is possible that different MprF proteins
sample different aminoacylated-tRNA substrates under different environmental conditions
[48]. This may be directly related to the availability of these donor molecules within the
intracellular aminoacyl-tRNA pool at the time, which is likely to change based upon the
growth conditions of the bacterium. Alternatively, MprF expression could be down
regulated under such conditions to reduce the detrimental effect of competition with the
translation machinery for the same aminoacylated-tRNA donor molecules.
3.2. VlmA mediated valanimycin synthesis in Streptomyces viridifaciens
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Within the genome of S. viridifaciens there is a 14-gene cluster encoding for the
biosynthesis of the naturally occurring azoxy-containing antibiotic, valanimycin.
Valanimycin is derived from L-Val and L-Ser via isobutylamine and isobutylhydroxylamine
intermediates. Encoded within the valanimycin biosynthesis gene cluster, there is a
dedicated class II seryl-tRNA synthetase, VlmA. VlmA is only 39% homologous to the
other housekeeping seryl-tRNA synthetase found within this actinomycete. This can be
explained by the different substrate specificity of VlmA, which is responsible for the
transfer of L-Ser from Ser-tRNASer to the hydroxyl group of isobutylhydroxylamine. The
product of the VlmA catalyzed reaction is O-(L-seryl)-isobutylhydroxylamine, which is
subsequently able to rearrange spontaneously to form N-(L-seryl)-isobutylhydroxylamine
[55,56]. The reaction catalysed by VlmL is essential for efficient production of valanimycin
as demonstrated by gene disruption studies. Phenotypic effects seen in a vlmA mutant
suggest that the Ser-tRNASer produced by the S. viridifaciens housekeeping seryl-tRNA
synthetase can be directed into valanimycin production but very inefficiently. Potential
explanations for this have included the possible compartmentalization of the valanimycin
pathway within this bacterium or inability of VlmA to access the full set of tRNASer
isoacceptors in the cell [57]. The mechanisms for directing tRNASer into the valanimycin
pathway rather than translation have not been fully characterized.
3.3. PacB mediated pacidamycin biosynthesis in Streptomyces coeruleorubidus
Genome mining within S. coeruleorubidus has resulted in the identification of a biosynthetic
gene cluster that allows this bacterium to synthesize members of the anti-pseudomonal
pacidamycin family of antibiotics [58]. Pacidamycins are broadly defined as a group of
uridyl tetra- or pentapeptide antibiotics that target the MraY translocase in the prokaryotic
peptidoglycan biosynthesis pathway [59]. The common scaffold for all pacidamycins is
based upon a central Nβ-methyl 2S, 3S-diaminoburytic acid (DABA) moiety. The DABA
FEBS Lett. Author manuscript; available in PMC 2014 September 17.
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moiety typically has an N-terminal amino acid (Ala/m-Tyr2) and a bicyclic heterocycle or
dipeptide (Ala/Gly1-m-Tyr2). In addition, there is a C-terminal ureido dipeptide (Ala4-Phe/
Trp/m-Tyr5) and a carboxy-linkage to a 3’-deoxy-4’, 5’-enaminouridine [60]. Production of
the 5’aminouridyl-tetrapeptide pacidamycin framework requires a total of nine
nonribosomal peptide synthetases [61]. Specifically, PacN generates the ureido dipeptide
moiety of the scaffold and PacD subsequently ligates this to the α-amino region of DABA.
DABA is then further modified at the carboxyl group by PacI-catalyzed addition of an
amide-linked modified uridine moiety. Addition of the N-terminal Ala/Gly1 has been shown
to require PacB, a structural homologue of W. viridescens FemX (see section 2.4 of this
review). PacB has functional similarity to the Fem ligases due to its role in the transfer of LAla from aminoacyl-tRNA donors to the m-Tyr2 residue of the growing PacH-anchored
antibiotic scaffold. No pacidamycin-dedicated aminoacyl-tRNA synthetases or tRNAs have
been found within the gene cluster encoding the components for synthesis of this class of
antibiotic. This suggests that PacB must sequester aminoacyl-tRNA donors in direct
competition with the protein synthesis pathway [62]. The mechanism by which this is
achieved and controlled is currently unknown.
3.4. Cyclodipeptide synthesis
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Cyclodipeptides form a large class of natural secondary metabolites that belong to the
diketopiperazine (DKP) family [63]. Many of these secondary metabolites are potentially
clinically relevant exhibiting a broad range of biological activities [64,65] including those
that are antibacterial [66–68], antifungal [69,70], antiviral [71], immunosuppressive [72],
antitumor [73–76] or anti-inflammatory [77] in nature. Initial characterization of
cyclodipeptide synthesis pathways resulted in the hypothesis that nonribosomal peptide
synthetases are essential to the process due to their role in catalysis of DKP scaffold
formation [63]. In 2002, a nonribosomal peptide synthetase-independent DKP biosynthesis
pathway was discovered in Streptomyces noursei [78]. Characterization of this albonoursin
synthesis pathway identified a unique tRNA-dependent cyclodipeptide synthase, AlbC.
AlbC is catalytically responsible for the synthesis of the albonoursin precursor cyclo(L-PheL-Leu) from Phe- and Leu-tRNA substrates. This precursor is then converted to albonoursin
by a cyclic dipeptide oxidase that is responsible for two sequential α,β-dehydrogenations
[63,78]. Since the discovery of AlbC, two other prokaryotic cyclodipeptide synthaserequiring pathways have been characterized. Synthesis of the cyclo(L-Leu-L-Leu) precursor
for the iron chelator, pulcherrimin, in Bacillus subtilis requires the Leu-tRNA-dependent
cyclodipeptide synthase, YvmC. After its synthesis, cyclo(L-Leu-L-Leu) is then converted
to the iron-binding unit, pulcherriminic acid, by CypX-catalyzed diketopiperazine ring
oxidation [63,79]. In Mycobacterium tuberculosis, the cyclo(L-Tyr-L-Tyr) precursor for the
potential cell viability factor mycocyclosin is produced by the Tyr-tRNA-dependent
cyclodipeptide synthase Rv2275. Following its synthesis, the cyclo(L-Tyr-L-Tyr) precursor
is subjected to C-C aryl coupling by CYP121 to form the final mycocyclosin product
[63,80,81]. Following elucidation of the pathways employed by these three cyclodipeptide
synthases, it has been determined that they form a unique family of enzymes detected across
at least 50 different bacterial genomes. The enzyme family is most well represented across
Actinobacteria, Proteobacteria and Firmicutes but they have also been found in
Bacteroidetes, Chlamydiae, Cyanobacteriae and five eukaryotic genomes. Despite this fairly
broad evolutionary distribution, cyclodipeptide synthases show very little to no significant
structural and functional similarity to the non-ribosomal peptide synthetases or Fem ligases.
Sequence alignment of nine members of this family has resulted in identification of
conservation at only seven residues (Gly-35, Ser-37, Gly-79, Tyr-128, Tyr-178, Glu-182 and
Tyr-202) and no apparent essential consensus sequence was found (reviewed in [82]).
Therefore, it is currently unclear how the cyclodipeptide synthases hijack aminoacylatedtRNA species from primary metabolism (Fig. 5).
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In addition to their primary role in translation, aminoacyl-tRNAs are also critical substrates
for other cellular processes including peptidoglycan biosynthesis, membrane lipid
modification, protein tagging for N-end rule degradation (reviewed in [83]), synthesis of
other tRNAs to compensate for an absent aminoacyl-tRNA synthetase (reviewed in [84]),
tetrapyrrole synthesis (reviewed in [84]), antibiotic biosynthesis and antibiotic resistance
pathways. With recent advances in post-genomic techniques ensuring the frequent discovery
of novel aminoacyl-tRNA-dependent pathways, there is renewed interest in both the proteins
that are involved in hijacking these substrates from primary metabolism and in the
associated mechanisms that ensure this does not become detrimental to the cell.
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The mechanism for ensuring adequate diversion of aminoacylated-tRNA donor molecules
into peptidoglycan biosynthesis, thereby surpassing direct competition from the translation
machinery, depends upon the bacterium and, in some cases, is still not fully understood. In
S. aureus, three of the five encoded tRNAGly isoacceptors escape protein synthesis and are,
instead, directed into pentaglycine peptidoglycan cross-bridge formations by virtue of them
containing sequence specific identity elements that are associated with weak binding to EFTu. In S. epidermidis, both Ser and Gly are found within the penta-amino acid peptidoglycan
cross-bridge, and at least two of the identified tRNAGlyisoacceptors (named IA and IB)
participate in peptidoglycan synthesis but not in translation [46,85]. Both of these tRNA
molecules differ from others in that their dihydrouridine (D) loops contain an unusually low
number of modified uridine nucelotides as well as lacking guanine at positions 18 and 19. In
addition to this, the D-loop of IB has two opposing uridine residues that prevent the normal
formation of the first base pair of this stem structure. In both species, the typical GTΨC
sequence found in many tRNAs is replaced by GUGC and there is an additional base pairing
event in the anticodon loop, between C32 and G38, which may distort this region enough to
prevent binding to the ribosome, thus accounting for efficient escape into peptidoglycan
biosynthesis [86,87]. In contrast, no single species of tRNASer or mutations within this
molecule have been identified that would allow it to act as an exclusive Ser donor for
peptidoglycan biosynthesis. In fact, it has been demonstrated that Ser is integrated into the
penta-amino acid bridge of this bacterium in a random manner and approximately 20% of
the cross-links within S. epidermidis strain Texas 26 consist solely of Gly [88]. This
suggests that Ser integration could be regulated by growth conditions or environmental
factors that would make it beneficial for Ser-tRNASer to be hijacked away from protein
synthesis. For example, it would be advantageous for S. epidermidis to increase levels of Ser
in its peptidoglycan cross-bridges during colonization of a niche inhabited by other
staphylococcal species that are able to produce and secrete glycyl-glycine endopeptidases
[31,32]. This is plausible when it is taken into consideration that the two well characterized
glycl-glycine endopeptidase secreting staphylococcal species, S. simulans and S. capitis
(reviewed in section 2.3), have both been isolated from human skin, which is also the
common niche of S. epidermidis [89].
Since indirect peptidoglycan cross-linking has only been directly correlated with cell
viability in members of the genus Staphylococcus, it is of no surprise that the Fem ligases
within this bacterium are provided with designated non-proteinogenic tRNAGly isoacceptors
to perform this task. No such designated tRNA isoacceptors have been identified in S.
pneumoniae or W. viridescens, the two other well characterized bacterial systems that
exhibit Fem ligase mediated indirect peptidoglycan cross-linking. MurMN from S.
pneumoniae require Ser-tRNASer and Ala-tRNAAla as amino acid donors whereas W.
viridescens FemX requires only the latter species. In both cases, attempts to characterize the
substrate specificities of W. viridescens FemX and S. pneumoniae MurM have indicated that
they only accept the amino acid moiety from the 2’ hydroxyl of adenine-76 of the tRNA
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donor molecule [41,90]. This contrasts with the described specificity of the ribosome, which
utilizes tRNA species that are aminoacylated on the 3’ hydroxyl group of adenine-76 [42].
Spontaneous transesterification of the amino acid between the 3’ and the 2’ hydroxyl group
of the terminal adenine of any tRNA molecule ensures that these species exist in a 2:1 ratio
at equilibrium [91]. Therefore this differential specificity of MurM and FemX in comparison
to the ribosome may be one mechanism that is exploited by the cell to ensure adequate
provision of aminoacyl-tRNA species for translation and peptidoglycan biosynthesis.
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In addition to mechanisms based on dedicated tRNAs, some non-ribosomal biosynthetic
pathways depend on dedicated aminoacyl-tRNA synthetases. Some MprF proteins, most
notably LysX in Mycobacterium tuberculosis, have a bound tRNA synthetase enzyme that is
dedicated to providing the MprF part of the protein with its charged tRNA substrate [50].
The valanimycin antibiotic biosynthesis pathway in S. viridifaciens has a dedicated seryltRNA synthetase that is responsible for production of the Ser-tRNASer intermediate [55].
Within these systems, presence of a dedicated synthetase could directly address the problem
of substrate competition with the translation machinery by ensuring the required aminoacyltRNA species are directly transferred to the proteins involved in these pathways without
being subjected to sampling by EF-Tu. The pacidamycin and characterized cyclodipeptide
biosynthesis pathways do not encode dedicated aminoacyl-tRNA synthetase enzymes and
are likely to hijack aminoacylated-tRNA donors directly from primary metabolism [58,82].
Therefore, the balance between translation and these pathways may shift in favour of the
later during stages in the growth cycle when production of these compounds is advantageous
to the bacterium. How this is achieved is currently unknown and further studies are required
to fully understand the interactions of these proteins with their tRNA substrates [62,82].

5. Future perspectives
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Aminoacyl-tRNA species are the prevalent amino acid donors in the cell due to their critical
role as substrates for ribosomal protein biosynthesis. It has become increasingly clear that
aminoacyl-tRNAs are also utilized in an ever-growing number of other non-ribosomal
biosynthetic pathways particularly in bacteria, although some pathways also exist in
eukaryotes [92]. To date over half of the 20 canonical aminoacyl-tRNAs required to
translate the genetic code have been shown to have one or more alternative functions in
bacteria, and it is likely that many more will be found to have roles in other pathways in all
domains of life. As discussed here, there is a clear link between many of the non-ribosomal
aminoacyl-tRNA dependent activities and antibiotic resistance or production, and other
stress responses. As a result of this, further characterization of these pathways may enable
development of methodologies for increasing the yield of natural antibiotic biosynthesis.
More importantly, research into these pathways will also provide the potential for
identification of new drug targets, which could restore the potency of antibiotics already
used in the clinical setting. Of particular interest here may be the discovery of “missing
links” in some of these non-ribosomal aminoacyl-tRNA dependent pathways, which might
be expected to fall into two broad categories. Firstly, it is possible that non-canonical
aminoacylation events may provide new and useful substrates to diversify non-ribosomal
biosynthetic pathways just as they do for protein synthesis [93]. Secondly, the partitioning of
substrates away from protein synthesis may require the presence of dedicated complexes
either between know factors [94], which in some cases may be fused [50], or the presence of
as yet uncharacterized factors that can sequester substrates for non-ribosomal pathways.
Overall, it seems clear that our current understanding of the role of aminoacyl-tRNAs
outside of protein synthesis will continue to expand and add to our broader understanding of
how translation and other cellular pathways are linked.
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Figure 1. Formation of an amino acid-tRNA pair by an aminoacyl-tRNA synthetase (aaRS)
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An amino acid (blue) is activated by an aaRS to form an aminoacyl-adenylate. This process
requires adenosine triphosphate (ATP) and results in the release of pyrophosphate (PPi).
Following tRNA binding to the aaRS, the activated amino acid is transferred to the 3’ end of
the tRNA molecule forming aminoacyl-tRNA with concurrent release of adenosine
monophosphate (AMP). The aminoacyl-tRNA product is released from the aaRS and is
either subject to binding by elongation factor Tu (EF-Tu) for delivery to the ribosome or
hijacking by other factors for diversion into biosynthetic pathways outside of translation.
Figure reproduced with permission from [2].
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Figure 2. Cellular biosynthetic pathways that utilize aminoacyl-tRNAs as substrates
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Figure 3. The role of MurM and MurN in cell wall branching using Lipid II as substrate

Lipid II is comprised of N-acetylated disaccharide units of glucosamine (yellow hexagon
labeled G) and muramic acid (pink hexagon labeled M). The pentapeptide side chain is
enzymatically attached to the muramic acid residues. Lipid II itself is anchored via
bactoprenyl pyrophosphate (pink zig-zag line) to the plasma membrane. MurM is an
aminoacyl ligase responsible for the addition of either L-Ser or L-Ala to the cell-wall
precursor L-Lys residue. MurN is responsible for the invariable addition of L-Ala as the
second amino acid of the cross-link. Reproduced with permission from [9].
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Figure 4. Partitioning of Lys-tRNALys between protein synthesis and membrane lipid
modification by MprF proteins

Lys-specific MprF (LysPGS) and Elongation factor Tu (EF-Tu) show comparable affinities
for Lys-tRNALys potentially allowing this aminoacylated tRNA species to enter two
different biosynthetic pathways simultaneously. Reproduced with permission from [95].
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Figure 5. Hijacking of aminoacylated-tRNA donor molecules by cyclodipeptide synthases for use
in biosynthesis of the natural secondary metabolites, cyclodipeptides

Aminoacylated-tRNA donor molecules are generated by aminoacyl-tRNA synthetases
(aaRS, shown in red). Typically the aminoacylated-tRNA product of the aaRS catalyzed
reaction is bound by elongation factor Tu (EF-Tu) and delivered to the ribosome (shown in
green) for use in protein synthesis. Cyclodipeptide synthases (blue) must hijack certain
aminoacylated tRNA species and divert them into the cyclodipeptide biosynthesis pathway.
Putative steps in the pathway are shown in italics. Reproduced and modified with
permission from [82].
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